Sage Therapeutics Inc Reports Results For The Quarter Ended In June: Earnings Summary

Sage Therapeutics

31/07/2024 22:23

* SAGE Therapeutics Inc  SAGE.OQ  reported a quarterly
adjusted
loss of $1.70​​ per share for the quarter ended in June, higher
than the same quarter last year, when the company reported EPS
of $-2.68.  The mean expectation of twenty analysts for the
quarter was for a loss of $1.66 per share. Wall Street expected
results to range from $-1.88 to $-1.17 per share.
    * Revenue rose 250.4% to $8.65 million from a year ago;
analysts
expected $8.85 million. 
    * SAGE Therapeutics Inc's reported EPS for the quarter was a
loss
of $1.70​.
    * The company reported a quarterly loss of $102.85 million.
    * SAGE Therapeutics Inc shares had fallen by 0.6% this
quarter and
lost 50.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 0.3%
in the last three months.​ 
    * In the last 30 days, five analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 17
"hold" and 2 "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"

Wall Street's median 12-month price target for SAGE Therapeutics
Inc is $12.50 
This summary was machine generated from LSEG data July 31 at
09:22 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -1.66          -1.70          Missed
 Mar. 31 2024      -1.65          -1.80          Missed
 Dec. 31 2023      -1.28          -1.80          Missed
 Sep. 30 2023      -2.73          -3.37          Missed